Sequencing Strategies in mCRPC
An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic castration-resistant prostate cancer (mCRPC) without prior androgen receptor pathway inhibitor exposure, while other combinations such as radium-223 plus olaparib showed mixed results with concerning toxicity profiles.